RxDoctor Payments Data

Gary Myron, MD

Family Medicine · Lake Geneva, WINPI 1386773174

Payments from drug & device makers

$414in general payments, 2019–2025

Across 14 payments — averaging $29.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$150
  • Medtronic$91
  • Pfizer$74
  • GSK$55
  • Novo Nordisk$19
  • AstraZeneca$13
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$414100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific1$150
Medtronic1$91
Pfizer5$74
GSK4$55
Novo Nordisk1$19
AstraZeneca1$13
Merck1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$414 in reported general payments places this provider in the 75th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$79,959
Medicare patients
395
Services billed
1,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$100,678
OzempicSemaglutide47$75,214
TrulicityDulaglutide34$51,740
XareltoRivaroxaban62$39,721
FarxigaDapagliflozin Propanediol27$37,195
JardianceEmpagliflozin31$34,169
JanuviaSitagliptin Phosphate28$29,985
EntrestoSacubitril/Valsartan13$20,589
TradjentaLinagliptin14$19,732
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$18,559
Tresiba Flextouch U-100Insulin Degludec12$11,065
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$9,863
Breo ElliptaFluticasone/Vilanterol14$7,137
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$7,095
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$6,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$74$100,67897 claims
Novo NordiskOzempic$19$75,21447 claims
AstraZenecaFarxiga, Symbicort$13$41,29241 claims
MerckJanuvia$12$29,98528 claims
GSKBreo Ellipta$55$7,13714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in Lake Geneva

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →